Impressively, a treatment with the phytopharmaceutical causes a concentration-dependent inhibition of tumor marker paxillin and simultaneously an enhanced E-cadherin-containing plaque deposition in HCT-116 and RKO cells [39]. This evidence concerns the gene PXN and neoplasm.